Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 30, 2019
Daily News
October 30, 2019
- Roche Going Beyond Oncology to Rev Up Precision Medicine Drive in Ophthalmology, Neuroscience
October 30, 2019
- Healthcare Providers Fret over Safety of Alternatives to Ranitidine amid Recalls
October 30, 2019
- AstraZeneca’s Japan R&D Chief Tapped as Medical Affairs SVP for Global Oncology Biz
October 30, 2019
- PMDA Reviewing ILD Risks for Erleada, Xtandi
October 30, 2019
- Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months
October 30, 2019
- MHLW Orders Label Revisions for Takecab to Include Pancytopenia to ADR List
October 30, 2019
- Nichi-Iko to Succeed 2 Off-Patent Brands from Astellas
October 30, 2019
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…